You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

375 Results
Cette plateforme contient des outils et des ressources pour les prestataires de soins primaires, les colposcopistes et d’autres professionnels de la...
Dans tout l’Ontario, les centres de cancérologie, les hôpitaux et les cliniques proposent une vaste gamme de services de dépistage, de diagnostic et...
Guidelines and Advice
Status: Current
Updated
Mar 2025
The resources in this toolkit will help radiologists and other imaging professionals provide consistent and high-quality imaging according to best...
Guidelines and Advice
Status: In-Review
ID: 19-4
Dec 1969
Regimen
Cancer Type:
Hematologic
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    iBRUtinib - In Combination with Rituximab for Previously Treated Waldenstrӧms Macroglobulinemia
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Ibrutinib for Previously Treated Waldenstrӧms Macroglobulinemia
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Ibrutinib for Previously Treated Waldenstrӧms Macroglobulinemia
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
iBRUtinib,
riTUXimab,
riTUXimab (subcut)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Guidelines and Advice
Status: In-Review
ID: 15-12
Version: 2
Jan 2015
Document
Dec 1969
Document
Dec 1969
Document
Dec 1969
Document
Dec 1969

Pages